Key Takeaways
- • CVC Capital Partners and Groupe Bruxelles Lambert (GBL) launched a €10.7 billion take-private bid for Italian pharmaceutical company Recordati at €51.29 per share, triggering significant shareholder opposition.
- • Shareholders have formally written to Recordati's board contending that CVC's offer price substantially undervalues the company and accusing the private equity consortium of applying pressure to accept a "lowball" valuation.
- • The tender offer represents a delisting attempt that has unified investor dissent, with multiple shareholders questioning whether the proposed price adequately reflects Recordati's operational performance and market value.
- • Recordati's first-half revenue growth of 6.6% driven by rare diseases segment expansion provides ammunition for shareholders arguing the company merits a higher valuation than CVC's proposed terms.
Summary
CVC Capital Partners, partnering with Belgian holding company Groupe Bruxelles Lambert, has initiated a controversial take-private bid for Recordati, the Italian specialty pharmaceutical manufacturer, valuing the company at €10.73 billion. The consortium tabled a tender offer of €51.29 per share to acquire the company, but the proposal has encountered organized shareholder resistance that threatens deal completion.
Shareholders have escalated their objections by formally communicating with Recordati's board, arguing that CVC's offer price materially undervalues the Italian drugmaker. Investors have characterized the bid as a "lowball" proposal and accused CVC of leveraging its position to pressure shareholders into accepting unfavorable terms. This coordinated shareholder response represents a significant challenge to deal momentum, as institutional investors demand better terms or threaten to withhold support for the delisting transaction.
The shareholder revolt gains credibility from Recordati's recent operational performance. The company reported first-half revenue growth of 6.6%, with particular strength in its rare diseases segment—a high-margin therapeutic area that typically commands premium valuations in specialty pharma. This demonstrable business momentum and segment expansion underpin shareholder arguments that the current offer price fails to capture the company's intrinsic value and growth trajectory.
The dispute centers on whether CVC's valuation reflects fair value for a profitable specialty pharmaceutical business with documented growth and a focused rare diseases franchise. The transaction requires shareholder approval, and the organized resistance from institutional investors creates material uncertainty around deal execution. The outcome will likely hinge on whether CVC and GBL adjust their offer price or face prolonged negotiations and potential deal failure.
Shareholders have escalated their objections by formally communicating with Recordati's board, arguing that CVC's offer price materially undervalues the Italian drugmaker. Investors have characterized the bid as a "lowball" proposal and accused CVC of leveraging its position to pressure shareholders into accepting unfavorable terms. This coordinated shareholder response represents a significant challenge to deal momentum, as institutional investors demand better terms or threaten to withhold support for the delisting transaction.
The shareholder revolt gains credibility from Recordati's recent operational performance. The company reported first-half revenue growth of 6.6%, with particular strength in its rare diseases segment—a high-margin therapeutic area that typically commands premium valuations in specialty pharma. This demonstrable business momentum and segment expansion underpin shareholder arguments that the current offer price fails to capture the company's intrinsic value and growth trajectory.
The dispute centers on whether CVC's valuation reflects fair value for a profitable specialty pharmaceutical business with documented growth and a focused rare diseases franchise. The transaction requires shareholder approval, and the organized resistance from institutional investors creates material uncertainty around deal execution. The outcome will likely hinge on whether CVC and GBL adjust their offer price or face prolonged negotiations and potential deal failure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.